Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by OBI Pharma, Inc
Information provided by (Responsible Party):
OBI Pharma, Inc Identifier:
First received: January 19, 2012
Last updated: October 24, 2013
Last verified: July 2012

The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.

Condition Intervention Phase
Metastatic Breast Cancer
Biological: OPT-822/OPT-821
Biological: Phosphate Buffer Saline (PBS)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by OBI Pharma, Inc:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Progression or up to 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 342
Study Start Date: December 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OPT-822/OPT-821
OPT-822 (equivalent to 30 μg of Globo H) in PBS mixed with OPT-821 (100 μg) PBS.
Biological: OPT-822/OPT-821
Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37 (visit 3, 4, 5, 7, 9, 11, 13, 15, and 18).
Placebo Comparator: Phosphate Buffer Saline (PBS) Biological: Phosphate Buffer Saline (PBS)
Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37 (visit 3, 4, 5, 7, 9, 11, 13, 15, and 18).


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female subjects ≥ 21 years of age with histological or cytological diagnosis of breast carcinoma.
  • Subjects with metastatic breast cancer who have achieved stable disease (SD), partial response (PR), or complete response (CR) after at least 1 regimen of anticancer therapy (i.e. chemotherapy or target therapy, either alone or in any combination). Involvement of supraclavicular lymph node is considered metastasis.
  • Subjects must have recovered from toxicities of prior therapies. (i.e. CTCAE ≤ grade 2).
  • Performance status: ECOG ≤ 1 and life expectancy ≥ 3 months.
  • Organ Function Requirements - Subjects must have adequate organ functions as defined below:

    • AST/ALT ≤ 3X ULN (upper limit of normal)
    • AST/ALT ≤ 5X ULN [with underlying Liver Metastasis]
    • Total Bilirubin ≤ 2.0 X ULN
    • Serum Creatinine ≤ 1.5X ULN
    • ANC ≥ 1500 /μL
    • Platelets > 100,000/μL
    • No Symptomatic Congestive Heart Failure (Ejection Fraction EF ≥ 50%)
  • Ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.
  • All positive or negative ER (estrogen receptor), PR (progesterone receptor), and HER-2 subjects are eligible for this study.
  • However, subjects who are HER-2 positive and responsive to anti-HER-2 therapy (e.g. Herceptin), are encouraged to remain on anti-HER-2 therapy and not enroll in this trial.
  • Subjects who desire to enroll in this study and for whom anti-HER-2 therapy is not available or contraindicated, may be eligible to enroll in this trial.
  • In countries where continuous anti-HER2 therapy is considered standard of care for HER-2 positive metastatic disease, HER-2 positive subjects are not eligible.
  • Women of childbearing potential must be willing to implement adequate contraception during the study. An adequate method of contraception will be at the investigator's discretion.

Exclusion Criteria:

  • Subjects are pregnant or breast-feeding at entry.
  • Subjects with more than 2 events of disease progression after the development of metastatic breast cancer.
  • Subjects who are currently receiving any other concomitant anticancer therapy with the EXCEPTION of bisphosphonates and hormone therapy.

    • During the study period, subjects using hormonal therapy and bisphosphonates should maintain a constant dose and should not change existing regimen.
    • However, if a change in hormonal therapy is indicated, e.g. due to intolerable adverse effects, the regimen may be modified but change should be minimized thereafter.
  • Subjects with metastasis limited to the bone only are excluded. However, subjects with current metastasis limited to the bone only and with a history of distant metastasis are eligible. Subjects with current metastasis limited to the bone only and with current breast tissue lesion are eligible.
  • Subjects who have any history of other malignancy (except non-melanoma skin carcinoma and carcinoma-in-situ of the uterine cervix) within 5 years of study entry.
  • Subjects with splenectomy.
  • Subjects with HIV infection.
  • Subjects with any major autoimmune diseases or autoimmune disorders requiring systemic iv/oral steroids or immunosuppressive or immunomodulatory therapies.

    • e.g. Type 1 juvenile onset diabetes mellitus, antibody positive for rheumatoid arthritis, Grave's disease, Hashimoto's thyroiditis, lupus, scleroderma, systemic vasculitis, hemolytic anemia, immune mediated thrombocytopenia, etc
    • Autoimmune disorders confined to the skin (e.g. psoriasis) are eligible, and topical steroids are allowed for the treatment of such skin disorders.
  • Subjects with any known uncontrolled inter-current illness including ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Subjects with any of the following MEDICATIONS within 4 weeks prior to randomization:

    • Anti-neoplastic agents
    • Immunotherapy [mAbs, Interferons, Cytokines (except GCSF)]
    • Immunosuppressants (e.g. Cyclosporin, Rapamycin, Tacrolimus, Rituximab, Alemtuzumab, Natalizumab, etc.).
    • Another investigational drug
  • Subjects with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently.
  • Subjects with any known severe allergies (e.g. anaphylaxis) to any active or inactive ingredients in the study drugs.
  • Subjects with bladder inflammation and urinary outflow obstruction.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01516307

Contact: Wayne Liaw, Ph.D 858-909-0736
Contact: Jane Willkomm 646-225-7024

United States, Alabama
The University of Alabama at Birmingham (UAB) Recruiting
Birmingham, Alabama, United States, 35294
United States, California
St. Jude Heritage Healthcare, Virginia K. Crosson Cancer Center Recruiting
Fullerton, California, United States, 92835
University of California, San Diego (UCSD) Recruiting
La Jolla, California, United States, 92093
University of California, Irvine (UCI) Recruiting
Orange, California, United States, 92868
University of California, San Francisco (UCSF) Recruiting
San Francisco, California, United States, 94115
Coastal Integrative Cancer Care Recruiting
San Luis Obispo, California, United States, 93401
Central Coast Medical Oncology Corporation Recruiting
Santa Maria, California, United States, 93454
University of California, Los Angeles (UCLA) Recruiting
Santa Monica, California, United States, 90404
United States, Florida
Memorial Regional Hospital Recruiting
Hollywood, Florida, United States, 33021
United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
United States, New York
Weill Cornell Medical College Recruiting
New York, New York, United States, 10065
United States, North Carolina
Hope Women's Cancer Center Recruiting
Asheville, North Carolina, United States, 28801
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Queen Mary Hospital Recruiting
Hong-Kong, China
Changhua Christian Hospital Recruiting
Changhua County, Taiwan
Chang Gung Memorial Hospital-KS Recruiting
Kaohsiung, Taiwan
Kaohsiung Medical University Hospital Recruiting
Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital Recruiting
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital -Linkou Recruiting
Linkou, Taiwan
Mackay Memorial Hospital Recruiting
New Taipei City, Taiwan
Taichung Veterans General Hospital Recruiting
Taichung, Taiwan
China Medical University Hospital Recruiting
Taichung, Taiwan
National Cheng Kung University Hospital Recruiting
Tainan, Taiwan
Chi Mei Medical Center Recruiting
Tainan City, Taiwan
Tri-Service General Hospital Recruiting
Taipei, Taiwan
Chang Gung Memorial Hospital-Taipei Recruiting
Taipei, Taiwan
Shuang-Ho Hospital Recruiting
Taipei, Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center Recruiting
Taipei City, Taiwan
Taipei Veterans General Hospital Recruiting
Taipei City, Taiwan
Sponsors and Collaborators
OBI Pharma, Inc
  More Information

No publications provided

Responsible Party: OBI Pharma, Inc Identifier: NCT01516307     History of Changes
Other Study ID Numbers: OPT-822-001
Study First Received: January 19, 2012
Last Updated: October 24, 2013
Health Authority: United States: Food and Drug Administration
Taiwan : Food and Drug Administration
Taiwan: Center for Drug Evaluation
Taiwan: Institutional Review Board
Hong Kong: Department of Health
Hong Kong: Ethics Committee

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on July 20, 2014